Peregrine to Report Third Quarter Fiscal Year 2013 Financial Results After Market Close on March 12, 2013

Peregrine to Report Third Quarter Fiscal Year 2013 Financial Results After 
Market Close on March 12, 2013 
TUSTIN, CA -- (Marketwire) -- 03/05/13 --  Peregrine Pharmaceuticals,
Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company
developing first-in-class monoclonal antibodies focused on the
treatment and diagnosis of cancer, today announced that it will
report financial results for the third quarter of the fiscal year
(FY) 2013 on March 12, 2013 after market and will host a conference
call and webcast at 1:30 PM Pacific Daylight Time (4:30 PM Eastern
Daylight Time). Peregrine's senior management will discuss financial
results for the third quarter ended January 31, 2013 of FY 2013 and
will review recent progress of its clinical development programs. 
To listen to the live webcast, or access the archived webcast, please
visit: http://ir.peregrineinc.com/events.cfm. 
To listen to the conference call, please dial (877) 312-5443 or (253)
237-1126 and request the Peregrine Pharmaceuticals call. A replay of
the call will be available starting approximately two hours after the
conclusion of the call through March 19, 2013 by calling (855)
859-2056, or (404) 537-3406 and using passcode 18046320. 
About Peregrine Pharmaceuticals, Inc.
 Peregrine Pharmaceuticals,
Inc. is a biopharmaceutical company with a portfolio of innovative
monoclonal antibodies in clinical trials focused on the treatment and
diagnosis of cancer. The company is pursuing multiple clinical
programs in cancer with its lead product candidate bavituximab and
novel brain cancer agent Cotara(R). Peregrine also has in-house cGMP
manufacturing capabilities through its wholly-owned subsidiary Avid
Bioservices, Inc. (www.avidbio.com), which provides development and
biomanufacturing services for both Peregrine and outside customers.
Additional information about Peregrine can be found at
www.peregrineinc.com. 
Contact:
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals, Inc.
(800) 987-8256
info@peregrineinc.com 
 
 
Press spacebar to pause and continue. Press esc to stop.